REDES study: Mepolizumab is effective in patients with severe eosinophilic asthma and comorbid NP

Introduction: REDES was a multicenter, retrospective, observational, real world study on the effectiveness and safety of 100 mg SC mepolizumab in Severe Eosinophilic Asthma (SEA) patients in Spain (n=318). Methods: This post hoc analysis described the demographic features and mepolizumab effectiveness according to the presence or absence of comorbid NP, a condition commonly present in an eosinophilic severe asthmatic phenotype. Results: 147 (46.2%) patients had a diagnosis of comorbid NP, with baseline eosinophils levels of 799 eos/µL (SEA without NP: 634 eos/µL). After 12 months of mepolizumab therapy, SEA+NP patients experienced an 83.4% reduction in annual exacerbation rates (SEA without NP: 73.0%, p=0.0017) and 53.7% of patients requiring maintenance therapy with oral corticosteroids were able to completely discontinue (SEA without NP: 42.9%). At the end of the year, all SEA patients also had improved asthma control, 76.0% with ACT>20 in SEA+NP vs 69.8% in SEA without NP, and improved their lung function: 0.23L in FEV1 (pre-BD) in SEA+NP vs 0.18L in SEA without NP (intergroup p=ns). Conclusion: Whilst mepolizumab is an effective treatment for SEA patients with and without a diagnosis of comorbid NP, those with SEA+NP represent a clinical phenotype who respond particularly well to mepolizumab therapy. Funding:GSK (ID 213172)